scholarly journals Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

2014 ◽  
Vol 58 (9) ◽  
pp. 1297-1307 ◽  
Author(s):  
Jean B. Nachega ◽  
Jean-Jacques Parienti ◽  
Olalekan A. Uthman ◽  
Robert Gross ◽  
David W. Dowdy ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Randomized Controlled Trials ◽  
Antiretroviral Treatment ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Pill Burden ◽  
Once Daily ◽  
Treatment Regimens ◽  
Randomized Controlled

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials

AIDS ◽  
1999 ◽  
Vol 13 (4) ◽  
pp. 501-507 ◽  
Author(s):  
Heiner C. Bucher ◽  
Lauren E. Griffith ◽  
Gordon H. Guyatt ◽  
Philippe Sudre ◽  
Marcel Naef ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Isoniazid Prophylaxis

Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 7556-7556
Author(s):  
Yucai Wang ◽  
Shouhao Zhou ◽  
Fang Yang ◽  
Grzegorz S. Nowakowski ◽  
Thomas Matthew Habermann ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Pairwise Comparison ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Controlled Trials ◽  
Treatment Regimens ◽  
Randomized Controlled ◽  
Frontline Treatment

7556 Background: The frontline treatment for advanced follicular lymphoma has evolved with the introduction of maintenance therapy, bendamustine (Benda), obinutuzumab (G), and lenalidomide (Len). We conducted a network meta-analysis of phase 3 randomized controlled trials (RCTs) to identify the regimens with superior efficacy. Methods: Data were extracted from 7 RCTs (FOLL05, StiL NHL1, BRIGHT, PRIMA, GALLIUM, StiL NHL7, and RELEVANCE). Progression-free survival (PFS) was compared between 11 regimens with different immunochemotherapy and maintenance strategies. To incorporate direct and indirect comparisons, random-effects Bayesian network meta-analyses were conducted after adjusting for study-wise variation. The posterior inference was derived based on Markov chain Monte Carlo methods and implemented using JAGS v4.3.0. Pairwise comparison of hazard ratios (HRs) and 95% credible intervals (CIs) were calculated. Results: PFS HRs of other regimens compared to the reference regimen are summarized in the Table. Compared to Rituximab(R)-Benda, R-CHOP had inferior PFS, R-CHOP-R, G-CHOP-G, and R-Len-R had similar PFS, while R-Benda-R, R-Benda-R4 and G-Benda-G had better PFS. Compared to R-CHOP-R, G-CHOP-G and R-Len-R had similar PFS, while R-Benda-R, R-Benda-R4 and G-Benda-G had better PFS. In addition, the PFS for G-Benda-G was similar to R-Benda-R4 (HR 0.94, 95% CI 0.78-1.09) but better than R-Benda-R (HR 0.82, 95% CI 0.75-0.97). Conclusions: Compared with the commonly used R-Benda and R-CHOP-R regimens, G-CHOP-G, R-Benda-R and R-Benda-R4 had better PFS, while the chemotherapy-free regimen R-Len-R had similar PFS. [Table: see text]

scholarly journals Compliance with Once-Daily versus Twice or Thrice-Daily Administration of Antibiotic Regimens: A Meta-Analysis of Randomized Controlled Trials

PLoS ONE ◽  
2015 ◽  
Vol 10 (1) ◽  
pp. e0116207 ◽  
Author(s):  
Matthew E. Falagas ◽  
Apostolos K. A. Karagiannis ◽  
Theodora Nakouti ◽  
Giannoula S. Tansarli
Keyword(s):  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Daily Administration ◽  
Controlled Trials ◽  
Once Daily ◽  
Randomized Controlled

Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials

2020 ◽  
Vol 75 (11) ◽  
pp. 3109-3119 ◽  
Author(s):  
Fabian Y S Kong ◽  
Christina L Hatzis ◽  
Andrew Lau ◽  
Deborah A Williamson ◽  
Eric P F Chow ◽  
...  
Keyword(s):  
Randomized Controlled Trials ◽  
Treatment Efficacy ◽  
Meta Analysis ◽  
Small Sample ◽  
Bibliographic Databases ◽  
Controlled Trials ◽  
Sample Sizes ◽  
Treatment Regimens ◽  
Randomized Controlled ◽  
Effective Treatments

Abstract Background Rising gonorrhoea rates require highly effective treatments to reduce transmission and prevent development of antimicrobial resistance. Currently the most effective treatments for pharyngeal gonorrhoea remain unclear. This review aimed to estimate treatment efficacy for pharyngeal gonorrhoea. Methods Online bibliographic databases were searched for the period 1 January 2000 to 17 September 2019 for treatments of gonorrhoea. All randomized controlled trials (RCTs) with data on pharyngeal gonorrhoea among participants aged 15 years or above, published in English, were included. Meta-analyses (random effects) were used to estimate the treatment efficacy, defined as microbiological cure, among currently recommended monotherapies and dual therapies, previously recommended but no longer used regimens and emerging drugs under evaluation. Side effects were also summarized. The study protocol was registered on PROSPERO (CRD42020149278). Results There were nine studies that included 452 participants studying 19 treatment regimens. The overall treatment efficacy for pharyngeal gonorrhoea was 98.1% (95% CI: 93.8%–100%; I2 = 57.3%; P < 0.01). Efficacy was similar for single (97.1%; 95% CI: 90.8%–100.0%; I2 = 15.6%; P = 0.29) and dual therapies (98.0%; 95% CI: 91.4%–100%; I2 = 79.1%; P < 0.01). Regimens containing azithromycin 2 g or ceftriaxone were similarly efficacious. The summary efficacy estimate for emerging drugs was 88.8% (95% CI: 76.9%–97.5%; I2 = 11.2%; P = 0.34). Small sample sizes in each trial was a major limitation. Conclusions Regimens containing ceftriaxone or azithromycin 2 g, alone or as part of dual therapies are the most efficacious for pharyngeal gonorrhoea. Further pharyngeal-specific RCTs with adequate sample sizes are needed.

Sign in / Sign up

Export Citation Format

Share Document